136390-01-7

Basic information

• Product Name: ethyl [2-(4-methoxyphenyl)ethyl]carbamate
• Synonyms: carbamic acid, N-[2-(4-methoxyphenyl)ethyl]-, ethyl ester
• CAS NO: 136390-01-7
• Molecular Formula: C₁₂H₁₇NO₃
• Molecular Weight: 223.2683
• Mol File: 136390-01-7.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 362.8°C at 760 mmHg
• Flash Point: 173.2°C
• Density: 1.073g/cm³
• Vapor Pressure: 1.89E-05mmHg at 25°C
• Refractive Index: 1.505
• PKA: 12.66±0.46(Predicted)
• CAS DataBase Reference: ethyl [2-(4-methoxyphenyl)ethyl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl [2-(4-methoxyphenyl)ethyl]carbamate(136390-01-7)
• EPA Substance Registry System: ethyl [2-(4-methoxyphenyl)ethyl]carbamate(136390-01-7)

Safety Data

• Hazardous Substances Data: 136390-01-7(Hazardous Substances Data)

Upstream product

• 64-17-5 ethanol 
• 541-41-3 chloroformic acid ethyl ester 
• 55-81-2 4-Methoxyphenethylamine 

Downstream Products

• 22246-04-4 7-methoxy-3,4-dihydro-2H-isoquinolin-1-one 
• 4091-50-3 N-methylhomoanisylamine 
• 43207-78-9 7-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 913613-99-7 7-hydroxy-2-methyl-3,4-dihydroisoquinolin-1(2H)-one 

Relevant articles and documents

Isoquinolinone derivatives as potent CNS multi-receptor D2/5-HT1A/5-HT2A/5-HT6/5-HT7 agents: Synthesis and pharmacological evaluation

In this study, a series of novel Isoquinolinone derivatives were synthesized as potential multi-target antipsychotics. Among these, compound 13 showed high affinity for dopamine D2 and serotonin 5-HT1A, 5-HT2A, 5-HT6, and 5-HT7 receptors, showed low affinity for off-target receptors (5-HT2C, H1, and α1), and negligible effects on ether-a-gogo-related gene (hERG; i.e., reduced QT interval prolongation). An animal behavioral study revealed that compound 13 reversed APO-induced hyperlocomotion, MK-801-induced hyperactivity, and DOI-induced head twitch. Moreover, compound 13 exhibited a high threshold for acute toxicity, a lack of tendency to induce catalepsy, and did not cause prolactin secretion or weight gain when compared to risperidone. Furthermore, in the forced swim test, tail suspension test, and novel object recognition test, treatment with compound 13 resulted in improvements in depression and cognitive impairment. In addition, compound 13 had a favorable pharmacokinetic profile in rats. Thus, the antipsychotic drug-like effects of compound 13 indicate that it may be useful for developing a novel class of drugs for the treatment of schizophrenia.

Preparation method of amide-like derivative and intermediate thereof

The invention discloses a preparation method of an amide-like derivative and an intermediate thereof. The invention provides a preparation method of a compound as shown in a formula VI and an intermediate thereof, the compound as shown in the formula VI c

Intramolecular Reductive Cyclization of o-Nitroarenes via Biradical Recombination

A visible-light-induced/thiourea-mediated intramolecular cyclization of o-nitroarenes under mild conditions is realized for the first time, which provides an efficient and environmentally friendly way to access pharmaceutical relevant quinazolinone derivatives. The reaction can be easily extended to gram level by using a continuous-flow setup with high efficiency. Mechanistic investigation including control experiments, transient fluorescence, UV-vis spectra, and DFT calculations suggests that the formation of active biradical intermediates via intramolecular single electron transfer (SET) is key stage in the catalytic cycle.